March 14, 2022

Solid Biosciences Reports 2-Year Efficacy and Safety Data from Ongoing Phase I/II IGNITE DMD Clinical Trial of SGT-001

Solid Biosciences has shared an update from IGNITE DMD, an ongoing Phase I/II clinical trial evaluating its gene therapy candidate SGT-001 in participants with Duchenne. In the announcement, Solid reports positive two-year efficacy and safety…

Learn More

March 14, 2022

The Lancet Publishes Positive Results from Capricor’s Phase 2 Study of CAP-1002 in Late-Stage Duchenne

Capricor Therapeutics has announced that The Lancet has published positive results from the company’s HOPE-2 Phase 2 clinical trial evaluating CAP-1002 in advanced stages of Duchenne. Findings from the study demonstrated that young men in the advanced stages…

Learn More

March 14, 2022

PPMD Awards $50,000 to the University of Pennsylvania for Launch of Duchenne and Becker Carrier Clinic Pilot

PPMD has always prioritized and advocated for optimal care for every person living with Duchenne and Becker. This began with the development of the care considerations, which translated into the standards by which PPMD’s Certified…

Learn More

March 9, 2022

PPMD’s Certified Duchenne Care Center Program – 2021 Impact & Progress

Every single person living with Duchenne deserves the best care possible. It is important that families know who is in charge of delivering the care they need and understand what centers are providing optimal, standardized…

Learn More

March 8, 2022

Action Alert! Support Progress in the Fight to End Duchenne

Urge your House and Senate Members to Support the FY 2023 Duchenne Funding Request & BENEFIT Act Today, during PPMD’s 2022 Advocacy Conference: Virtual Fly-In, over 260 advocates will be participating in 240+ virtual meetings…

Learn More

March 4, 2022

Race Athlete Spotlight: Austin Hogan

This year, Austin Hogan ran the Houston Half Marathon as part of the Race to End Duchenne team. Meet Austin Why did you choose to join the Race to End Duchenne team? Our family friend…

Learn More

February 22, 2022

PPMD’s Power of Us Summit Series: Caregiver registration is now open!

The Power of Us Summit Series — Registration for Parents, Grandparents & Caregivers Is Now Open! April 28-30, 2022 | Atlanta, GA The Power of Us is stronger than any of us alone. Over the…

Learn More

February 11, 2022

Connect with PPMD’s Care Team

At PPMD, we place immense value on personal connection with the Duchenne community to provide support and partner with you on this complex journey. As our organization continues to grow, we aim to remain present,…

Learn More

February 4, 2022

WATCH: FibroGen DMD Pamrevlumab Phase 3 Clinical Studies Highlight (Webinar Recording)

FibroGen joined PPMD for a webinar on February 2, 2022. During the webinar, FibroGen discussed the clinical rationale for the use of Pamrevlumab by highlighting its Phase 2 study in non-ambulatory participants with Duchenne and…

Learn More

February 3, 2022

New Study to Understand Duchenne Patients’ and Caregivers’ Attitudes Towards Gene Therapy Launched

In a new transatlantic collaboration, Parent Project Muscular Dystrophy (PPMD) and Duchenne UK (DUK), the DMD Hub, and RTI International are conducting a study to explore attitudes towards gene therapy and gene editing from adults…

Learn More